This small molecule is being tested by scientists at the ALS Therapy Development Institute for its potential to help support the unfolded protein response in ALS patients.
Since adding it in January of 2015, we've been able to rapidly move this compound into efficacy testing in SOD1 mice. We are hopeful it will show promise as a treatment for ALS.
Topics in the Pipeline
Register now for our upcoming webinar on May 10th at 6pm: FDA approves Radicava - What do we need to know?
#WHATWOULDYOUGIVE to #ENDALS?
For ALS Awareness Month, join our #InThreeWords campaign on social media.
You can be a hero and give to ALS TDI to help us get more promising treatments out of our lab and into people living with ALS.
November 27 is
You've taken the challenge, now help
move promising treatments out of our
lab and into people living with ALS.
The 2018 Combined Federal Campaign has officially launched!
Help us continue to move more potential treatments into the clinic!